cardiovascular,diabetes

GSK1940029 (SCD inhibitor 1) is an inhibitor of stearoyl-CoA desaturase (SCD).

Semaglutide TFA is a glucagon-like peptide-1 congener that induces weight loss, lowers blood glucose levels, and reduces cardiovascular risk in diabetic patients.Semaglutide TFA induces mild-to-moderate and transient gastrointestinal disturbances, and may be used in the study of type 2 diabetes and obesity.

CP-642931 (Sorbitol dehydrogenase-IN-1) is an orally active and highly potent sorbitol dehydrogenase inhibitor for the study of diabetes and cardiovascular disease.

GPR35 agonist 3 is a synthetic GPR35 agonist with an EC50 value of 1.4 μg in the β-arrestin recruitment assay.GPR35 agonist 3 is used in the study of cancer, type 2 diabetes, and cardiovascular disease.

AICAR (Acadesine) is an AMPK activator. AICAR has the functions of metabolic regulation, muscle function regulation, anti-cancer effect, neuroprotection and anti-aging.

Sotagliflozin (LX-4211, LP-802034) is an oral dual inhibitor of sodium-glucose cotransporter 1/2 (SGLT1/SGLT2) (SGLT2, IC₅₀ ≈ 1.8 nM; SGLT1, IC₅₀ ≈ 36 nM) used as an antidiabetic agent. Sotagliflozin is used in research on cardiovascular disease and diabetes.

Bisphenol A is an endogenous metabolic compound of phenols and is widely used in the production of epoxy resins and polycarbonate plastics. It is reproductive, developmental and systemic toxicant and is often classified as an endocrine disruptor. It has been linked to many diseases, including respiratory disease, cardiovascular disease, diabetes, kidney disease, obesity and reproductive disorders.

NSC-6038 (4-chloro-N,N-dipropylbenzamide) is a benzamide-based bioactive compound with a wide range of biological activities and has been shown to possess anti-inflammatory, antioxidant and anti-angiogenic activities, and has also been shown to be effective in the treatment of a wide range of diseases such as cancer, diabetes and cardiovascular diseases.

Sirtuin modulator 2 (N-(3-(imidazo[2,1-b]thiazol-6-yl)phenyl)-2-methoxybenzamide) exhibits antidiabetic, anti-inflammatory and antitumor activities.

TXNIP-IN-1 is an inhibitor of the TXNIP-TRX complex and used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease.

DGAT2-IN-3 (compound 9) is an inhibitor of DGAT2 with an IC50 value of 0.4 nM. It is utilized in research related to fatty liver disease, diabetes, and cardiovascular diseases.

Haptoglobin, Phenotype 2-2 is a plasma protein that binds hemoglobin (Hb) to remove free hemoglobin and possesses antioxidant activity. It can be utilized in research related to kidney failure and cardiovascular diseases associated with diabetes.

AMPK activator17 (Compound 10g) is an orally bioavailable AMPK activator. It significantly inhibits lipogenesis (IC50: 3.4 μM) and improves dyslipidemia. By activating the AMPK pathway, AMPK activator17 suppresses early adipocyte differentiation (mitotic clonal expansion) and enhances mitochondrial function and fatty acid oxidation in mature adipocytes. It improves dyslipidemia through promoting cholesterol reverse transport. AMPK activator17 is applicable in research on obesity and associated metabolic disorders, such as type 2 diabetes and cardiovascular diseases.

Glycation-IN-1 (Compound 3) is an inhibitor of the glycosylation reaction, effectively suppressing the synthesis of the initial, intermediate, and final products of glycation reactions. It is applicable in research on various chronic diseases, including diabetes, immune inflammation, cardiovascular diseases, and neurodegenerative disorders.

Picotamide monohydrate is a dual inhibitor of thromboxane A2 (TxA2) synthase and receptor. It exhibits antiplatelet activity and aids in reducing microalbuminuria and inhibiting carotid plaque growth in diabetes. This compound is applicable in research related to acute or chronic cardiovascular diseases.

p-F-HHSiD (p-Fluorohexahydrosiladifenidol) is a potent and selective antagonist of the M3 muscarinic acetylcholine receptor (M3mAChR). Additionally, it exhibits antagonistic effects on other M receptor subtypes and the α1-adrenoceptor (alpha1-adrenoceptor). This compound is applicable in research concerning cancer, metabolic disorders, neurological diseases, and cardiovascular conditions, including studies on colon cancer, Alzheimer's disease, and diabetes.

BI-9774 is an activator of 5' AMP-activated protein kinase (AMPK) with an IC50 ranging from 12 to 88 nM. It holds potential for research into metabolic disorders, such as type 2 diabetes and obesity, as well as cardiovascular diseases, including myocardial ischemia and heart failure.

Neuromedin U (NMU) is a neuropeptide first demonstrated to drive smooth muscle contraction.1Translated as a 174 amino acid propeptide, NMU is cleaved to different lengths in different animals. It has diverse receptor-mediated rolesin vivo, as it regulates feeding, vasoconstriction, nociception, and bone remodeling and contributes to obesity, cancer and septic shock.2,2NMU-25 is the active form of NMU in humans. It binds with high affinity to receptors on human left ventricle and coronary artery (KDs = 0.26 and 0.11 nM, respectively), eliciting endothelium-independent vasoconstriction.3NMU-25 also suppresses glucose-stimulated insulin secretion in human islets, and this effect is lost in NMU R165W mutants, resulting in early-onset obesity.4 1.Mitchell, J.D., Maguire, J.J., and Davenport, A.P.Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin SBritish Journal of Pharmacology15887-103(2009) 2.Greenwood, H.C., Bloom, S.R., and Murphy, K.G.Peptides and their potential role in the treatment of diabetes and obesityRev.Diabet.Stud.8(3)355-368(2011) 3.Mitchell, J.D., Maguire, J.J., Kuc, R.E., et al.Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular systemCardiovascular Research81353-361(2009) 4.Alfa, R.W., Park, S., Skelly, K.R., et al.Suppression of insulin production and secretion by a decretin hormoneCell Metabolism21(2)323-333(2015)

BTK-IN-5, a covalent inhibitor of Bruton's tyrosine kinase (BTK), is designed for treating cardiovascular diseases, respiratory diseases, inflammation, and diabetes.

Benzamide, 3-methoxy-N-(3-thiazolo[5,4-b]pyridin-2-ylphenyl) (3-methoxy-N-(3-(thiazolo[5,4-b]pyridin-2-yl)phenyl)benzamide) is a sirtuin modulator and useful for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including diabetes, cardiovascular disease, bloo

Sirtuin Modulator 4, a sirtuin modulator, exhibits an inhibitory effect on SIRT1, presenting an EC 50 value ranging from 51-100 μM. It is potentially useful in research aimed at prolonging cell lifespan and preventing a broad spectrum of diseases and disorders such as diabetes, obesity, neurodegenerative, cardiovascular diseases, inflammation, and cancer.

Lipoprotein lipase (LPL) is an enzyme, mainly involved in lipid metabolism, that hydrolyzes triglycerides in lipoproteins.LPL can be a target for obesity/diabetes-related cardiovascular diseases and has an important role in lowering triglyceride levels and improving cardiovascular.

Sirtuin Modulator 5, a sirtuin modulating agent, activates SIRT1 with an efficacy marked by a DC50 value of less than 50 μM. It is applicable in enhancing cell longevity and is researched for its therapeutic potential in a wide range of diseases such as those associated with aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, blood clotting disorders, inflammation, cancer, and flushing. Furthermore, it holds promise for conditions that could benefit from boosted mitochondrial activity [1].

Gevokizumab (S-78989) is a humanised monoclonal antibody targeting IL-1β, which blocks IL-1β signalling through allosteric regulation, and can be used for diabetes, cancer, inflammation, and cardiovascular diseases.